{"title":"粘蛋白屏障对环肽体外膜通透性的影响。","authors":"Yuji Sakurai, Kazuhisa Ozeki, Haruka Tsutsui, Terushige Muraoka, Kimio Terao","doi":"10.1016/j.ejps.2025.107254","DOIUrl":null,"url":null,"abstract":"<div><div>This study investigated the role of the mucin layer in cyclic peptide permeability using an <em>in vitro</em> assay system. We evaluated the membrane permeability of 18 cyclic peptides and reference compounds using biosimilar mucin and Caco-2/HT29 cells. The permeability of paracellular markers (FD4 and LY) and digoxin (a low molecular weight compound) remained unaffected by mucin presence when using biosimilar mucin. Conversely, cyclosporin A, a commercially available cyclic peptide drug, showed reduced permeability. In Caco-2/HT29 co-cultured cells compared with Caco-2 cells only, most compounds exhibited increased permeability due to enhanced interstitial permeability, except for cyclosporin A, which showed decreased permeability in the presence of mucin. Similarly, the permeability of LUNA18, a cyclic peptide under development, was reduced by 54.1 and 26.0 % in both Caco-2/HT29 co-cultured and HT29 cells. Furthermore, 12 of 18 cyclic peptides exhibited ≥ 2-fold decrease in membrane permeability in Caco-2/HT29 co-cultured cells. These findings suggest that current permeability evaluation methods, which do not account for the mucin layer, may overestimate the permeability of highly lipophilic cyclic peptides. The mucin layer may serve as a rate-limiting factor in cyclic peptide membrane permeability, highlighting the importance of including mucin layer permeability in cyclic peptide evaluation protocols.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"214 ","pages":"Article 107254"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of the mucin barrier on the in vitro membrane permeability of cyclic peptides\",\"authors\":\"Yuji Sakurai, Kazuhisa Ozeki, Haruka Tsutsui, Terushige Muraoka, Kimio Terao\",\"doi\":\"10.1016/j.ejps.2025.107254\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>This study investigated the role of the mucin layer in cyclic peptide permeability using an <em>in vitro</em> assay system. We evaluated the membrane permeability of 18 cyclic peptides and reference compounds using biosimilar mucin and Caco-2/HT29 cells. The permeability of paracellular markers (FD4 and LY) and digoxin (a low molecular weight compound) remained unaffected by mucin presence when using biosimilar mucin. Conversely, cyclosporin A, a commercially available cyclic peptide drug, showed reduced permeability. In Caco-2/HT29 co-cultured cells compared with Caco-2 cells only, most compounds exhibited increased permeability due to enhanced interstitial permeability, except for cyclosporin A, which showed decreased permeability in the presence of mucin. Similarly, the permeability of LUNA18, a cyclic peptide under development, was reduced by 54.1 and 26.0 % in both Caco-2/HT29 co-cultured and HT29 cells. Furthermore, 12 of 18 cyclic peptides exhibited ≥ 2-fold decrease in membrane permeability in Caco-2/HT29 co-cultured cells. These findings suggest that current permeability evaluation methods, which do not account for the mucin layer, may overestimate the permeability of highly lipophilic cyclic peptides. The mucin layer may serve as a rate-limiting factor in cyclic peptide membrane permeability, highlighting the importance of including mucin layer permeability in cyclic peptide evaluation protocols.</div></div>\",\"PeriodicalId\":12018,\"journal\":{\"name\":\"European Journal of Pharmaceutical Sciences\",\"volume\":\"214 \",\"pages\":\"Article 107254\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0928098725002520\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098725002520","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Impact of the mucin barrier on the in vitro membrane permeability of cyclic peptides
This study investigated the role of the mucin layer in cyclic peptide permeability using an in vitro assay system. We evaluated the membrane permeability of 18 cyclic peptides and reference compounds using biosimilar mucin and Caco-2/HT29 cells. The permeability of paracellular markers (FD4 and LY) and digoxin (a low molecular weight compound) remained unaffected by mucin presence when using biosimilar mucin. Conversely, cyclosporin A, a commercially available cyclic peptide drug, showed reduced permeability. In Caco-2/HT29 co-cultured cells compared with Caco-2 cells only, most compounds exhibited increased permeability due to enhanced interstitial permeability, except for cyclosporin A, which showed decreased permeability in the presence of mucin. Similarly, the permeability of LUNA18, a cyclic peptide under development, was reduced by 54.1 and 26.0 % in both Caco-2/HT29 co-cultured and HT29 cells. Furthermore, 12 of 18 cyclic peptides exhibited ≥ 2-fold decrease in membrane permeability in Caco-2/HT29 co-cultured cells. These findings suggest that current permeability evaluation methods, which do not account for the mucin layer, may overestimate the permeability of highly lipophilic cyclic peptides. The mucin layer may serve as a rate-limiting factor in cyclic peptide membrane permeability, highlighting the importance of including mucin layer permeability in cyclic peptide evaluation protocols.
期刊介绍:
The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development.
More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making.
Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.